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Abstract Inactivation by thiol reducing and alkylating agents 
of ligand binding to the human u-opioid receptor was examined. 
Dithiothreitol reduced the number of [3H]diprenorphine binding 
sites. Replacement by seryl residues of either C142 or C219 in 
extracellular loops 1 and 2 of the u. receptor resulted in a 
complete loss of opioid binding. A disulfide bound linking C142 
to C219 may thus be essential to maintain a functional 
conformation of the receptor. We also demonstrated that 
inactivation of ligand binding upon alkylation by N-ethylmalei-
mide occurred at two sites. Alteration of the more sensitive 
(ICso = 20 uM) did not modify antagonists binding but decreased 
agonist affinity almost 10-fold. Modification of the less reactive 
site (IC50 = 2 mM) decreased the number of both agonist and 
antagonist binding sites. The alkylation site of higher sensitivity 
to Af-ethylmaleimide was shown by mutagenesis experiments to 
be constituted of both C81 and C332 in transmembrane domains 
1 and 7 of the (i-opioid receptor. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Opioid receptors are the primary site of action of morphine 
and opiate alkaloids used in the treatment of pain. Three 
classes of opioid receptors, u\, 3 and K have been identify on 
the basis of their distinct pharmacological profiles, anatomical 
distributions and functions [1,2]. The cDNAs coding for these 
three opioid receptors have recently been cloned [3-10]. The 
deduced amino-acid sequences confirmed that each receptor 
displays structural characteristics of G-protein-coupled recep-
tors including seven hydrophobic cc-helical segments thought 
to constitute membrane spanning domains. 
Morphine analgesia as well as side effects such as addiction, 
euphoria and respiratory depression seem mostly mediated by 
the (J. receptor [11] possibly through coupling to multiple G-
protein isoforms [12,13]. Analysis of the structure/function 
relationships of the (J, receptor is thus of particular importance 
in view of the emerging concept of signalling-specific drugs 
[14-16]. 
In the absence of direct structural information, the engi-
neering of receptor genes and the chemical modification of 
functional groups constitute alternative approaches to inves-
tigate the role of particular residues in ligand recognition and/ 
or receptor structure. It has long been known that opioid 
binding is inhibited by sulfhydryl alkylating [17,18] and reduc-
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ing [19] agents such as iV-ethylmaleimide (NEM) and dithio-
threitol (DTT). The effects of NEM on the three opioid re-
ceptors are not identical. Their order of sensitivity is u > 6 > K 
[20]. Moreover, upon alkylation by NEM the number of bind-
ing sites is reduced for all three N,, 9 and K receptors but only 
the residual u\ and 9 receptors, and not K, display a reduced 
affinity for agonists [21-23]. Because NEM is able to shift u-
and 9-opioid receptors into a low-affinity state for agonists 
and because this effect is modulated by Na+ ions and GTP 
analogues [21,22], it remains unclear whether the -SH group(s) 
alkylated by NEM is located on the opioid receptors or on 
associated G-proteins. 
Previous studies on u-opioid receptors [20,22] were per-
formed on brain membranes which harbour the three classes 
of receptor. To precise the effects of sulfhydryl reducing or 
alkylating agents we used mammalian cells transfected with 
the human u-opioid receptor cDNA and thus expressing a 
single class of receptor. Mutagenesis experiments were also 
performed to identify the molecular determinants at the basis 
of DTT and NEM actions on u-opioid receptor. 
The inhibitory effect of DTT on ligand binding was attrib-
uted to the reduction of a disulfide bridge linking C142 and 
C219 in extracellular loops 1 and 2 of the u-opioid receptor. 
Alkylation of C81 and C332 occurred at low concentrations 
of NEM and decreased agonists but not antagonists binding; 
this effect is suggested to result from alteration of receptor 
interactions with agonists or with G-proteins. Modification 
of a second site of lesser sensitivity to NEM and which re-
mains to be identify, reduced the number of binding sites for 
both agonists and antagonists. 
2. Materials and methods 
2.1. Chemicals and reagents 
Tissue culture reagents and dithiothreitol were from GIBCO-BRL 
(Cergy-Pontoise, France). DEAE dextran was purchased from Phar-
macia (Saint-Quentin en Yvelines, France) and polyethylenimine, N-
ethylmaleimide, chloroquin and [D-Ala2, TV-Me-Phe4, Gly5-ol]-enke-
phalin (DAGO) from Sigma (St. Louis, MO). Morphine and naloxone 
were from Francopia (Paris France) and diprenorphine from Reckitt 
and Colman (Kingston, UK). [3H]Diprenorphine ([3H]DPN; 40 Ci/ 
mmol) and [3H]DAGO (55 Ci/mmol) were from Amersham (Little 
Chalfont, UK). Synthetic oligonucleotides (Genosys, Cambridge, 
UK) were purified by SDS-PAGE electrophoresis. DNA modifying 
and restriction enzymes were from New England Biolabs (Beverly, 
MA). 
2.2. Cloning and mutagenesis of the [i-opioid receptor cDNA 
A cDNA encoding the human (i-opioid receptor was amplified from 
SH-SY-5Y human neuroblastoma mRNA by RT-PCR using 5'-
cgtetag_aggcagaggagaatgtc-3' sense and 5'-cttctagacttggtgaaggtgga-3 ' 
antisense primers. These were derived from published sequences 
[24,25] modified to create Xbal sites (underlined) at the 5'-end of 
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each primer. The amplified fragment (1.5 kb) was cloned into the 
Xbal sites of pGEM4z and both strands entirely sequenced (Sequen-
ase version 2.0; USB, Cleveland, OH) using 14 sense and antisense 
internal primers. 
Silent substitutions were introduced into the u-opioid receptor 
cDNA to facilitate subsequent mutagenesis. Sail and ß™361 restric-
tion sites were created in the sequences coding for TST (positions 
120-122 in TM 2) and ALG (positions 325-327 in TM7). Using these 
and naturally occurring sites, short sequences were replaced by syn-
thetic oligonucleotides coding for the desired mutations and contain-
ing a restriction site convenient for mutant screening. Oligonucleo-
tides and restriction sites were: a 50 bp Bell to Banll fragment 
introducing a BsrGl site for C81S; a 69 bp Sail to BsaBl fragment 
introducing an Acc65l site for C142S; a 68 bp BsaBl to BspDl frag-
ment introducing a ferXI site for C161S; a 74 bp BamHl to BsrGl 
fragment introducing a Sacl site for C219S; a 39 bp ÄSH36I to Nsil 
fragment introducing an Accl site for C332S. Each construct was 
verified by restriction enzyme analysis and sequencing throughout 
the modified regions. A 1.3 kb Ncol to Xbal fragment containing 
the entire receptors coding region was then subcloned into the BamHl 
and Xbal sites of the pcDNA/Amp eukaryotic expression vector (In-
vitrogen, San Diego, CA). 
2.3. Receptor expression and binding assays 
Cos-M6 cells (5.10°) were transfected with plasmid DNA (15 ug) by 
the DEAE-dextran method and grown for 64 h at 37°C in a 5% C02 
atmosphere in DMEM supplemented with sodium glutamate (862 mg/ 
1), sodium pyruvate (110 mg/ml), foetal calf serum (10%), penicillin 
(50 U/ml) and streptomycin (50 ug/ml). After washing and harvesting, 
cell pellets were frozen at —80°C, thawed and resuspended in 50 mM 
Tris-HCl (pH 7.5) and 1 mM EDTA. After Potter homogenization 
(20 strokes, 4°C) and centrifugation (10 min, lOOOXg, 4°C), the pellet 
was re-homogenized in the same buffer and centrifuged as above. 
Supernatants were pooled and crude membranes were pelleted 
(lOOOOOXg and 4°C for 30 min) and resuspended in 50 mM Tris-
HCl (pH 7.4) and 1 mM EDTA to be aliquoted and stored at -80°C. 
Protein content was measured as described [26]. 
Saturation experiments were performed on membranes aliquots 
(20-100 ug of protein) in 0.5 ml of 50 mM Tris-HCl (pH 7.4), using 
13 concentrations (0.1-3 nM) of [3H]DPN, a non-selective opioid 
antagonist or [3H]DAGO (0.1-5 nM), a it-selective agonist. Inhibition 
of [3H]DPN (1 nM) binding was realized with 12 concentrations of 
competitors (10 pM to 20 or 200 U.M according to the selectivity of 
the inhibitor used). Non-specific binding was determined in the pres-
ence of 1 U.M unlabelled diprenorphine. Following a 1 h incubation 
period at 25°C, free ligand was removed by filtration on to Whatman 
GF/B filters and bound radioactivity was measured. Data were ana-
lyzed with the Inplot program (Graphpad Software Inc., San Diego, 
CA). 
2.4. Treatment with thiol reagents 
Membrane aliquots of COS-M6 cells transfected with u-opioid re-
ceptor cDNA were maintained for 10 min at 25°C in 50 mM Tris-HCl 
(pH 7.4), containing varying concentrations of either DTT (10-500 
mM) or NEM (0.05-8 mM). Alkylation by NEM was stopped by 
adding DTT in a 2-fold molar excess and further incubating for 10 
min at 25°C. Reactions were diluted 5-fold in ice-cold 50 mM Tris-
HCl (pH 7.4), and binding assays were performed. 
3. Results 
3.1. Cloning of the human \a-opioid receptor cDNA and 
expression in COS-M6 cells 
The coding region of the cDNA isolated from SH-SY-5Y 
neuroblastomas had a sequence identical to that of Mestek et 
al. [24] but differed from that of Wang et al. [25] at three 
positions, resulting in D51N (G/A) and L234V (GC/CG) sub-
stitutions. Transfection of this cDNA into COS-M6 cells re-
sulted in the expression of binding sites with K& values for 
[3H]DPN and [3H]DAGO, and K{ values for DAGO, mor-
phine and naloxone (Tables 1 and 2) which closely agreed 
with those previously reported for u receptors expressed in 
mammalian tissues or transfected cells [24,27-30]. 
3.2. Inactivation by dithiothreitol and N-ethylmaleimide of 
ligand binding to \i-opioid receptors 
The sensitivity of the u receptor to thiol reducing and al-
kylating agents was investigated by measuring [3H]DPN bind-
ing following treatment of membranes with varying concen-
trations of DTT or NEM. Both compounds completely 
inhibited [3H]DPN binding with half-effective concentrations 
(IC50) of 250 mM for DTT and 1 mM for NEM (Fig. 1). The 
lack of action of DTT at concentrations up to 20 mM ruled 
out the possibility that the decreased [3H]DPN binding ob-
served upon NEM treatment may be attributed to the DTT 
added to stop alkylation. 
The effect of NEM on [3H]DAGO binding was also ana-
lyzed since it has been reported that binding of agonists was 
more sensitive than that of antagonists to NEM inactivation 
[20]. The biphasic nature of the curve (Fig. 1) suggested that 
two distinct sites of alkylation were involved in inhibition by 
NEM of [3H]DAGO binding to the u-opioid receptor. The 
first one with an IC50 value of 20 uM seemed specific of 
agonists binding whereas the second one, the IC50 of which 
(2 mM) was in the same range as that for the inhibition of 
[3H]DPN binding, could be involved in inactivation of both 
agonist and antagonist binding. 
3.3. Consequences of DTT and NEM treatment on the number 
of \i-opioid binding sites and their affinity for agonists and 
antagonists 
Inhibition of opioid binding by DTT and NEM was further 
characterized by performing saturation experiments following 
reduction or alkylation of (i-opioid receptors. Scatchard's 
analysis [31] of [3H]DPN binding isotherms revealed that 
250 mM DTT reduced 5 m a x values from 1.7 to 0.7 pmol/mg 
Table 1 
Two alkylation sites of different sensitivity to NEM differentially affect [3H]DPN and [3H]DAGO binding to the |i-opioid receptor 
[3H]DPN [3H]DAGO 
(NEM) 
None 
50 uM 
1 mM 
(nM) 
0.21 ±0.03 
N.D. 
0.39 ±0.04 
(% of control) 
100 
N.D. 
42 ±5* 
(nM) 
0.95 ±0.16 
6.0 ±0.7* 
5.6 ±0.4* 
"max 
(% of control) 
100 
111 ± 15 
60 ±5* 
Dissociation constants (K^) and receptor densities (#max) were calculated by Scatchard's transformations of saturation isotherms following treat-
ment of COS-M6 membranes expressing the wild-type u-opioid receptor with the indicated concentrations of NEM. Bmax values varied from one 
transfection to another (1^1 pmol/mg of proteins) and are represented as the mean percentage ofthat occurring in the absence of NEM.*P<0.05 
treated versus untreated. 
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Table 2 
Effects of NEM on antagonists and agonists binding to wild-type and mutant u,-opioid receptors 
Receptors 
V-
U.C161S 
U.C81S 
U.C332S 
UC81S/C332S 
NEM 
— 
+ 
— 
+ 
— 
+ 
— 
+ 
— 
+ 
KA (nM) 
[3H]DPN 
0.21 ±0.03 
0.39 ±0.04 
0.20 ±0.03 
0.94±0.05b 
0.17 ±0.03 
0.30 ±0.04 
0.18 ±0.03 
0.20 ±0.03 
0.28 ±0.08 
0.21 ±0.06 
Naloxone 
3.7 ±0.3 
4.5 ±1.0 
1.8±0.8 
7.3±0.3b 
2.6 ±1.0 
3.5 ±0.7 
1.8 ±0.4 
1.9±0.1 
4.9 ±0.9 
2.5 ±0.3 
Ki (nM) 
Morphine 
9.5 ± 2.5 
82 ± 4a 
5.4 ± 1.0 
140 ±30b 
9.5 ± 2.7 
30 ± 3a 
9.8 ± 1.1 
28 ± 3a 
49 ± l l b 
48 ± 8 
DAGO 
7.5 ± 1.5 
55 ± 5a 
1.8 ± 0.3b 
100 ±20b 
4.3 ± 1.0 
18 ± 4a 
5.4 ± 0.3 
18 ± 7 
14 ± 1 
15 ± 1 
Dissociation (Kd) and inhibition (K\) constants were calculated from direct and inhibition assays of [3H]DPN binding to membranes of COS-M6 
cells expressing the wild-type (u) or the indicated mutant u-opioid receptors before (—) and after (+) treatment with 1 mM NEM for 15 min at 
25°C. Scatchard's analysis of [3H]DPN binding showed a mean reduction in the number of binding sites of 48% for the \i. receptor, 61% for (J.C161S, 
62% for HC81S, 54% for U.C332S and 53% for uC81S/C332S. Significant differences (P<0.05) between KA or K-, values of treated versus untreated 
receptors (a) and mutant versus wild-type receptors (b) are indicated. 
of membrane protein with no significant effect on the affinity 
of the residual sites (not shown). 
The affinity of [3H]DPN was not affected by 1 mM NEM 
which only reduced the number of binding sites by 50% (Fig. 
2 and Table 1). The density of [3H]DAGO binding sites was 
similarly decreased by 1 mM NEM but Kd value was in-
creased from 1 to 6 nM (Fig. 2 and Table 1). This differential 
effect on [3H]DAGO and [3H]DPN binding and the possible 
existence of two alkylation sites (see above) suggested that 
modification of the first site (IC50 = 20 uM) could have ac-
counted for diminished agonist affinity whereas alkylation of 
the second site (IC50 = 2 mM) could have resulted in decreased 
^max values. Indeed, upon exposure to 50 U.M NEM, the 
number of [3H]DAGO binding sites was not modified whereas 
the affinity of the ligand was decreased to the same extent as 
with 1 mM NEM (Fig. 2 and Table 1). 
The apparent affinities of other opioid ligands following 
NEM treatment were analyzed by competition binding assays 
[32]. These indicated that the inhibition constants (Kj) of na-
loxone, another opioid antagonist, was indeed unaffected by 
NEM and confirmed that K\ of agonists DAGO and mor-
phine were increased about 10-fold (Table 2). 
increased (Table 2). Surprisingly, the effect of NEM treatment 
on binding affinities was more pronounced for this mutant 
receptor than for the wild-type receptor (Table 2). As for 
n K 
1 2 3 
Log [DTT] (mM) 
3.4. Identification in the \i-opioid receptor of the cysteyl 
residues involved in inactivation by DTT and NEM 
Inactivation of other G-protein-coupled receptors by DTT 
has been attributed to the reduction of a disulfide bond link-
ing conserved cystein residues in extracellular loops 1 and 2 
[33-35]. To examine whether this was also the case here, the 
corresponding C142 and C219 of the (0,-opioid receptor were 
replaced by serine residues. COS-M6 cells transfected with 
cDNA coding for mutants (0.C142S or U.C219S receptors did 
not exhibit any specific binding to agonist [3H]DAGO or to 
antagonists [3H]DPN and [3H]naloxone (not shown). 
The |x-opioid receptor has been suggested to be more sensi-
tive to inactivation by NEM than 8 or K receptors [20]. To 
identify the molecular determinants of NEM action on the u.-
opioid receptor, C81, C161 and C332 which are specifically 
present in transmembrane domains 1, 3 and 7 (C81 is also 
found in the 9 receptor), were substituted by serine. 
The apparent affinities of [3H]DPN, naloxone and mor-
phine for the |J,C161S receptor were almost identical to those 
for wild-type receptor whereas that of DAGO was slightly 
T3 
C *-* 
3 •-* 
O O 
m (-
■D C 
C O 
<0 U 
100 
- 2 - 1 0 1 
Log [NEM] (mM) 
Fig. 1. Dithiothreitol and JV-ethylmaleimide inhibit ligand binding 
to the |i-opioid receptor. Residual binding of 1 mM [3H]DPN (o) 
and [3H]DAGO (•) was measured after incubation of membranes 
with increasing concentrations of DTT (upper panel) or NEM (low-
er panel). Each curve is representative of 2 to 3 experiments per-
formed in duplicate. 
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wild-type receptors, a 60% decrease in the number of binding 
sites was obtained. 
The binding profiles of u O l S and U.C332S receptors were 
not modified as compared to that of the native receptor (Ta-
ble 2). For both mutants, the number of [3H]DPN binding 
sites was decreased by about 50% upon receptor alkylation by 
NEM. The K^ values of agonists were also increased by NEM 
but to a lower extent than for the \i receptor. This suggested 
that alkylation of C81 and C332 may be responsible for the 
inhibition by NEM of agonist binding to the u. receptor. A 
receptor carrying both substitutions was thus constructed. 
Compared to the wild-type u-opioid receptor, the uC81S/ 
C332S receptor had unmodified affinities for antagonists and 
its affinity for agonists was decreased for morphine and to a 
lesser extent for DAGO (Table 2). Affinities of the double 
mutant for DAGO and morphine were no longer sensitive 
to NEM treatment (Table 2) whereas the number of binding 
sites was still decreased by 50% (Table 2). This loss of mod-
ulation of agonist binding was further evidenced by the dis-
appearance from the inhibition curve by NEM of [3H]DAGO 
Log [NEM] (mM) 
Fig. 3. Comparison of NEM effects on [3H]DAGO binding to wild-
type and C81S/C332S u-opioid receptors. Residual binding of 1 nM 
[3H]DAGO to wild-type (•) and C81S/C332S ( A ) u-opioid recep-
tors was measured following incubation with the indicated concen-
trations of NEM. Curves are representative of two experiments per-
formed in duplicate. 
[3H]DPN Bound (pmol/mg) 
9) 
c 
O 
m 
.06 
.04 
.02 
• < * . 
* \ 
3 ^ S ^ - B - ^ D 
* \ * 
0.5 1.3 
[3H]DAG0 Bound (pmol/mg) 
Fig. 2. Differential effects of NEM on [3H]DPN and [3H]DAGO 
binding to u-opioid receptors. Upper panel: Scatchard's plots of 
[3H]DPN binding isotherms for control (o) COS-M6 membranes 
and membranes treated with 1 mM NEM (A) . Lower panel: 
Scatchard's plots of [3H]DAGO binding isotherms for COS-M6 
membranes treated (O) or not (•) with 1 mM NEM. Curves are 
representative of 3 to 4 experiments performed in duplicate; the cor-
responding mean K^ and 5max values are given in Table 1. 
binding to the U.C81S/C332S receptor of the component of 
higher sensitivity to NEM which was observed for the wild-
type receptor (Fig. 3). 
4. Discussion 
4.1. A disulfide bridge connects extracellular loops 1 and 2 of 
the \a-opioid receptor 
Treatment of cell membranes expressing ix-opioid receptors 
with increasing concentrations of the thiol reducing agent 
DTT decreased the number of [3H]DPN binding sites. The 
high concentrations of DTT required to inactivate ligand 
binding may have resulted in non-specific deterioration of 
the cell membrane. Such an effect is, however, expected to 
be gradual and accompanied by a parallel loss of receptor 
affinity and that was not observed here. Alternatively, inacti-
vation of ligand binding could have arisen from the reduction 
within the |o.-opioid receptor of a disulfide bond barely acces-
sible to the solvent or of low reactivity to NEM. Indeed, 
mutant u-opioid receptors in which C142 and C219 in extrac-
ellular loops 1 and 2 were changed to serine both failed to 
bind agonists and antagonists. Since it is possible that (1C142S 
and |xC219S receptors were not expressed at the cell mem-
brane, our results suggest that the formation of a disulfide 
bound between extracellular loops 1 and 2 is necessary to 
constrain the u-opioid receptor in a proper conformation 
for ligand binding and/or for membrane integration. 
4.2. Differential effects of NEM on agonist and antagonist 
binding 
The inhibitory effect of NEM on ligand binding to the u.-
opioid receptor [20,22] was precised here using transfected 
COS-M6 cells expressing a homogenous receptor population. 
The EC50 of NEM for inhibition of [3H]DPN binding (1 mM) 
agreed with that measured for [3H]bremazocine [20], another 
opioid antagonist. We showed that the effects of NEM on 
[3H]DPN binding were mainly attributed to diminished bind-
ing capacity of cell membranes; the affinities of antagonists 
for |x-opioid receptors were almost unaffected. In contrast but 
in agreement with other reports [22], 1 mM NEM reduced 
both receptor density and affinity for agonists. Such a differ-
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ential effect of NEM on agonist versus antagonist binding has 
also been reported for 9-opioid receptors [21,36]. 
At lower concentrations of NEM (50 uM) only the affinity 
for the agonist [3H]DAGO was modified. This suggested that 
NEM is acting at two sulfhyldryl groups with alkylation of 
the more sensitive (IC50 = 20 itM) leading to altered agonists 
affinities and modification of the less reactive (IC50 = 1-2 mM) 
to decreased Bmax values. Similarly to our results, it has re-
cently been shown that inhibition by NEM of substance P 
binding to the NK-1 receptor occurred in a biphasic manner 
and that alkylation of the more sensitive site decreased affinity 
for the neuropeptide [37]. 
4.3. Alkylation by NEM of cysteine residues 81 and 332 in the 
\i-opioid receptor is responsible for decreased agonists 
affinity 
Cystein residues C161 and C332 which are specifically 
found in the it-opioid receptor, and C81 which also occurs 
in the 9 receptor, were replaced by serine residues to identify 
the molecular determinants of the inhibition by NEM of ago-
nists binding to the ^-opioid receptor. Each single mutation 
had no or little intrinsic effect on ligand binding. 
Antagonist binding to U.C161S receptors became sensitive to 
NEM and the loss in agonist affinity was even more pro-
nounced than for wild-type receptors. This could have re-
flected alkylation of a cysteine residue not exposed to NEM 
in wild-type receptor but accessible in uC161S, either as a 
result of a conformational change of the receptor structure 
or because it is normally forming a disulfide bridge with C161. 
Affinities of agonists for (xC81S and (xC332S receptors were 
partially protected from NEM action; total protection was 
obtained for the uC81S/C332S receptor. The 50% decrease 
in receptor density was still observed for the three mutant 
receptors. In agreement with this result, the NEM dose-re-
sponse curve for inhibition of [3H]DAGO binding to (iC81S/ 
C332S receptors did not any longer present the component of 
high sensitivity to NEM which was shown to be responsible 
for modulation of agonists affinities for the native u-opioid 
receptor. Alkylation by NEM of the n-opioid receptor at both 
C81 and C332 was thus certainly responsible for decreased 
agonists affinities. This correlates with previous studies which 
showed that \i receptors were more sensitive to NEM than 9 
and K [20], and that both _Bmax and K& values were affected for 
|0. and 9 receptors [21,22,36], whereas only the number of bind-
ing sites was decreased for K receptors [23]. Indeed the u, 
receptor contains two cysteins the alkylation of which results 
in decreased agonists affinities whereas the 9 receptor has only 
one of these (C81) and the K receptor none. 
In contrast with these results, it has recently been reported 
that H223 was critical for u-opioid receptor inactivation by 
NEM, and that cysteine residues were not involved [38]. The 
C332S substitution was, however, not investigated in this 
study [38]. Moreover, the effect of NEM on the binding of 
agonists could not be addressed since only the antagonist 
[3H]bremazocine was used. Therefore, as suggested [38], the 
effect of the uH223S substitution on NEM sensitivity could 
have resulted from a conformational change in the receptor 
structure. 
Because NEM is able to shift \i- and 9-opioid receptors into 
a low-affinity state for agonists, but not for antagonists, and 
because this effect is modulated by sodium and to a lesser 
extent by lithium, it has been suggested that the cysteine res-
idues alkylated by NEM could either belong to the opioid 
receptor and be involved in coupling to G-proteins or lie with-
in the G-protein itself [22,36]. Our results with the uC81S/ 
C332S receptor clearly argue against the latter possibility. In 
the former case, they suggest that coupling to G-proteins still 
occurs for u,C81S and |iC332S receptors since these display 
affinities for agonists which are identical to those of wild-type 
receptors and remain sensitive to NEM. Such substitutions 
may indeed be neutral in terms of coupling because the posi-
tion corresponding to |0.C332 is naturally occupied by a serine 
in 9 and K receptors. 
Although affinities of the double-mutant |iC81S/C332S for 
[3H]DPN, naloxone and DAGO were unaffected, that for 
morphine was slightly decreased. The C81 and C332 residues 
of the (a. receptor may thus be important for high-affinity 
morphine binding, either because they are, or lie in the close 
vicinity of, agonists contact points or because their simulta-
neous replacement induces discrete modifications of receptor 
interactions with morphine or G-proteins. In this respect it is 
interesting to note that DAGO and morphine have already 
been shown to induce different intracellular trafficking of \y-
opioid receptors [39,40], possibly by coupling to different G-
proteins and intracellular effectors. 
Altogether, ours results support the conclusion that in 
mammalian cells alkylation of (x-opioid receptors by NEM 
at C81 and C332 accounts for decreased agonist affinities. 
They also suggest that such an effect is due to modifications 
of receptor interactions with agonists or with G-proteins. Al-
kylation of other cystein residue(s) which still have to be iden-
tified but are expected to be common to \i, 9 and K receptors, 
may be responsible for the diminished i?max values observed 
for all three receptors upon NEM treatment. 
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